11 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 11 of 11 clinical reviews.
Evidence-based protocol for safely discontinuing alirocumab (Praluent), including LDL rebound data from ODYSSEY OUTCOMES, monitoring timelines, and when restarting PCSK9 inhibitor therapy is warranted.
Evidence-based guide to alirocumab (Praluent) food and supplement interactions. Covers statins, red yeast rice, omega-3s, grapefruit, vitamin D, and more with PubMed-cited clinical data.
A detailed look at how Praluent (alirocumab) is manufactured by Regeneron and Sanofi, its supply chain logistics, FDA shortage records, and what the patent war with Amgen meant for patient access.
Master the correct alirocumab (Praluent) self-injection technique with this guide covering pen use, site rotation, storage, and troubleshooting common errors.
A week-by-week guide to your first four weeks on Praluent (alirocumab): when LDL drops, what side effects appear, and what the ODYSSEY OUTCOMES trial data mean for your cardiovascular risk.
A clinical review of alirocumab (Praluent) use in patients with autoimmune disease, covering immunogenicity, drug interactions, trial data from ODYSSEY OUTCOMES, and practical prescribing guidance.
A clinician-level review of alirocumab (Praluent) hair loss and skin reactions, drawing on ODYSSEY trial data, FDA labeling, and primary literature to separate real adverse effects from coincidence.
Evidence-based guidance on when to pause alirocumab (Praluent) before surgery, covering pharmacokinetics, bleeding risk, lipid rebound, and restart timing for cardiovascular patients.
How to store Praluent (alirocumab), what stability data show, how long it lasts at room temperature, and the mechanism behind why proper storage matters for this PCSK9 inhibitor.
Board-reviewed protocols for traveling with alirocumab (Praluent), covering cold-chain storage, timezone-shifted dosing, airport security, and post-travel LDL monitoring. Backed by primary literature.
Evidence-based guide to switching between alirocumab (Praluent), evolocumab (Repatha), inclisiran (Leqvio), and other lipid-lowering therapies. Covers timing, dose equivalence, washout considerations, and LDL-C monitoring.